News

Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.

The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.

An overview of the complex relationships between herpes simplex virus, human papillomavirus, cytomegalovirus and HIV.

Younger transgender and gender diverse individuals see a greater stigma around PrEP, but experts are still unsure why.

Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, which accounted for nearly one-fifth of all pediatric hospitalizations in the U.S. before the pandemic.

At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.

When it comes to preventing and treating patients with HIV/AIDS, experts say to look towards the youth.

The number of biologics approved as treatments for psoriasis has proliferated but the FDA has approved just four for use in children. Six biologics for pediatric psoriasis are in various stages of development.

Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.

Inequalities throughout the world in treatment and prevention of HIV are not being addressed, with infection rates rising in the Middle East and north Africa, Eastern Europe and central Asia and Latin America.

Here’s what you missed this week on Managed Healthcare Executive.

Results of the American Society of Retina Specialists annual survey provide insight into opinions of its members and their current and future practice patterns.

Results from retrospective real-world studies presented at American Society of Retina Specialists annual meetiing put the risk of retinal vasculitis from Syfovre at 1 in 1,330 patients. But other results presented at the meeting supplied evidence that Syfovre fends off vision loss caused by geographic atrophy, an advanced form of dry age-related macular degeneration.

Session on diabetic retinopathy includes results from trials of a variety of approaches to retinopathy.

Findings from an analysis of data from the pivotal PHOTON trial didn't show any increased risk of higher intraocular pressure building from injections of the high-dose, 8-mg version of Eylea.

Part two focuses on the requirement that Part D sponsors must make enrollees aware of upcoming benefits.

American Indian and Alaska Native women also had higher comorbidities and less access to private insurance than White women.

But the presenter downplayed the rivalry between the two new treatments for geographic atrophy. “I think we are lucky to have multiple therapies,” saidPaul Hahn, M.D., Ph.D. of NJRetina.

How Long COVID-19 rates differ across the pre-delta, delta and omicron eras.

The study's results were presented today at the American Society of Retina Specialists meeting in Stockholm, Sweden, by Parisi Emami-Naeini, M.D., M.P.H., a retina specialist at the Tschannen Eye Institute at the UC Davis Eye Center.

But the Mayo Clinic ophthalmologist who presented the findings stressed that it was “hugely reassuring” the GLP-1s were comparable to older diabetes drugs with respect to retinopathy given all their other advantages.

Dr. Charles C. Wykoff discusses how a one-time gene therapy could benefit patients with wet age-related macular degeneration.

Dr. Charles C. Wykoff discusses interim results from a phase 2 trial of a gene therapy to treat with patients with wet age-related macular degeneration.

UnitedHealth is still feeling the impact of the Change Healthcare cyberattack.

Biosimilars generally enter the market priced at roughly 50% of the amount of their reference drugs.

Geoffrey G. Emerson of Retina Consultants of Minnesota and medical director at the Phillips Eye Institute in Minneapolis and an associate adjunct professor at the University of Minnesota, previews the 2024 annual meeting of the American Society of Retina Specialists (ASRS) starting Wednesday, July 17, in Stockholm, Sweden.

Grandmother and great-grandmother Donna Osborne had recently finished radiation therapy when she won the prize.

Developed by Vertex Pharmaceuticals, suzetrigine is a promising new class of pain medicine that has been gaining attention for its innovative mechanism of action and reported efficacy; suzetrigine might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.